A phase 1, first-in-human (FIH), dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 Posted on May 27, 2026July 31, 2026 by Stef Gesuero
Cartography does another pharma deal, this time with Pfizer Posted on January 6, 2026July 29, 2026 by Stef Gesuero
LY6G6D targeting with a T cell engager is a promising therapeutic for MSS colorectal cancer Posted on April 21, 2025July 29, 2026 by Stef Gesuero
Finding New Targets for Cancer Drugs: Kevin Parker on the Long Run Posted on April 14, 2025July 29, 2026 by Stef Gesuero Finding New Targets for Cancer Drugs: Kevin Parker on The Long Run
A CB21-targeted T cell engager is a promising therapeutic for the treatment of colorectal cancer Posted on November 5, 2024July 29, 2026 by Stef Gesuero
Cartography Biosciences gets on the map with $57M and an itinerary for next-gen cancer therapies Posted on July 19, 2022July 24, 2026 by Stef Gesuero
